Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

COX2/mPGES1/PGE2pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells

(2017) Victor Prima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer

(2016) Viriya Kaewkangsadan et al.   Journal of Immunology Research

Chimeric Antigen Receptor T Cells for Cancer Immunotherapy

(2015) Kevin J. Curran et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells

(2015) Jie Tang et al.   Journal of Materials Chemistry B

Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

(2015) Jiang Li et al.   OncoImmunology

Lipid–calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases

(2014) Yu-Cheng Tseng et al.   BIOMATERIALS

Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles

(2014) Li Li et al.   BIOMATERIALS

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhancing endosomal escape for nanoparticle mediated siRNA delivery

(2014) Da Ma   Nanoscale

PD-L1 expression and tumor-infiltrating lymphocytes

(2014) Kurt A Schalper   OncoImmunology

Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy

(2013) Yuan Zhang et al.   BIOMATERIALS

PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction

(2013) K. Abiko et al.   CLINICAL CANCER RESEARCH

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

(2013) Michael Kalos et al.   IMMUNITY

How Does the Cell Overcome LCP Nanoparticle-Induced Calcium Toxicity?

(2013) Yu-Cheng Tseng et al.   MOLECULAR PHARMACEUTICS

Codelivery of VEGF siRNA and Gemcitabine Monophosphate in a Single Nanoparticle Formulation for Effective Treatment of NSCLC

(2013) Yuan Zhang et al.   MOLECULAR THERAPY

An influenza virus-inspired polymer system for the timed release of siRNA

(2013) Nghia P Truong et al.   Nature Communications

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2

(2013) Stéphanie Cochaud et al.   Scientific Reports

Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment

(2012) Jianjian Jin et al.   JOURNAL OF IMMUNOTHERAPY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine

(2011) Elizabeth A. Vasievich et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor

(2011) Jun Li et al.   JOURNAL OF CONTROLLED RELEASE

Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know

(2011) Steven A. Rosenberg   Nature Reviews Clinical Oncology

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy

(2010) Yunching Chen et al.   MOLECULAR THERAPY

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

(2009) G. Solinas et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses

(2009) W. Gu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Costimulation blockade in autoimmunity and transplantation

(2008) Flavio Vincenti   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY